But, since nearly all anesthetic and analgesic drugs affect anticancer immunity and other tumor-promoting pathways (such as angiogenesis and VEGF) [21–23], ketorolac represents only one of the perioperative drug candidates to reduce the risk of recurrence [5, 24]. This evidence concerns the gene VEGFA and neoplasm.